BRACE-AFibNCT07904507
A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation
StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Interventions modified
- Secondary endpoints: details revised at 3 of 4 entries
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Atrial-Fibrillation-related Quality of Life
Timeframe: From baseline to 3 months
Secondary (4)
NT-proBNP
6-minute walking test (6MWT) distance
Peak flow measurement
Hierarchical composite endpoint comprising
Arms and interventions
DiltiazemExperimental
133 patients are randomized to the experimental intervention and treated with the non-dihydropyridine calcium channel blocker (NDCC) Diltiazem.
BisoprololActive comparator
133 patients are randomized to the control arm and treated with the beta-blocker Bisoprolol.
Drugs: Diltiazem, Bisoprolol
Sites
1 site in 1 country
- University Hospital BaselBasel, Canton of Basel-City, Switzerland